ORSI, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 109
EU - Europa 91
AS - Asia 55
Continente sconosciuto - Info sul continente non disponibili 1
Totale 256
Nazione #
US - Stati Uniti d'America 109
IT - Italia 34
SE - Svezia 33
CN - Cina 30
SG - Singapore 21
RU - Federazione Russa 16
IN - India 4
DE - Germania 3
IE - Irlanda 3
FI - Finlandia 2
EU - Europa 1
Totale 256
Città #
Ashburn 15
Boardman 14
Shanghai 14
Singapore 13
Milan 12
New York 10
Lawrence 7
Princeton 7
Moscow 6
Carlsbad 5
Seattle 4
Turin 4
Dallas 3
Dublin 3
Hyderabad 3
Rome 3
Beijing 2
Berlin 2
Cuneo 2
Modena 2
New Haven 2
Reggio Emilia 2
San Maurizio Canavese 2
Verdellino 2
Brescia 1
Fort Worth 1
Guangzhou 1
Helsinki 1
Jiaxing 1
Lappeenranta 1
Los Angeles 1
Pisa 1
Pune 1
Shaoxing 1
Shenzhen 1
St Petersburg 1
Washington 1
Weitang 1
Totale 153
Nome #
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 22
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 22
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 18
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 18
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 18
The impact of nutritional status on pancreatic cancer therapy 17
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 17
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 16
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 14
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants 14
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 13
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 13
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 12
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 11
Pancreatic cancer: still a cold case? 11
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples 11
Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? 11
Lessons and open questions in borderline resectable pancreatic cancer 9
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 8
null 8
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 8
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 8
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 3
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 1
Totale 303
Categoria #
all - tutte 3.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.967


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 5 3 0 0 1
2022/202368 14 11 5 0 1 16 3 10 2 0 6 0
2023/2024157 12 9 12 31 15 18 5 15 4 10 5 21
2024/202569 39 11 19 0 0 0 0 0 0 0 0 0
Totale 303